Preparation of Lysine-based DTPA as a BFCA for Radioimmunotherapy

Mi-Sun Pyun, Young-Don Hong, Kang-Hyuk Choi and Sun-Ju Choi*

Radioisotope Research & Development Lab, HANARO Center, Korea Atomic Energy Research Institute

Dukjin-dong 150, Yuseong-gu, Daejeon, Republic of Korea, 305-353,

Email: choisj@kaeri.re.kr

1. Introduction

During the past decade, many bifunctional chelating agents (BFCAs) have been studied, synthesized and used for radiopharmaceuticals especially for labeling of antibodies and regionally selective drugs. General researches for preparation of DTPA derivatives have been performed using cyclic DTPA dianhydride. Because one or two carboxylic groups of DTPA were used to conjugate with biomolecule results to lower chelating power for radionuclides.

Our goal was to synthesize new bifunctional chelating agents for their application in development of new medical imaging and therapeutic agents. To obtain more effective new chelating agents, we focused on the development of DTPA derivatives whose original functional groups are intact. In our study, we described the synthesis of a DTPA analogue derived from lysine.

2. Methods and Results

The preparation scheme and chemical structures of all the intermediate compounds are indicated in scheme 1.



Scheme 1. Preparation of lysine-based DTPA.

2.1.1 N_{ε} -(tert-butoxycarbonyl)-L-lysine methylester (1) from **a**

To a suspension of L-lysine (1.0g, 5.5 mmol) in CH₃OH, chlorotrimethylsilane (2.43ml, 19.2 mmol) was dropwisely added for 10min. After stirring for 24hrs, the reaction mixture was evaporated in vacuo to give the crude product (about 1.1 g) as a white powder. Without any further purification, crude product was dissolved in 2 drops of water, CH₃OH(20 ml), and triethylamine (4 ml), the solution of Di-tert-butyl-dicarbonate (1.31, 6.0 mmol) in CH₂Cl₂ (4 ml) was added for 10 min at 10 °C and stirred overnight. The reaction mixture was reduced to 3 ml volume and purified using flash column

chromatography with gradient condition $(CH_2Cl_2/CH_3OH 95:5)$ to yield 86% of product 1.

2.1.2 1 N_{ε} -(tert-butoxycarbonyl)-L-lysine methylester (2) from **b**

A solution of diazomethane $(35 \text{ mmol})^5$ in diethyl ether (30 mmol) was added cautiously portionwise to a stirred solution of N_e-(tert-butoxycarbonyl)-L-lysine (1g, 4.1 mmol) in CH₃OH (10 mL) at 0°C. The reaction mixture was maintained under N₂ condition and stirred at room temperature for 4 hrs. Evaporation of the solvent under reduced pressure gave the product 1 with quantitative yield.

2.1.3 N_{ε} -(tert-butoxycarbonyl)-L-lys(tBu4-DTPA) methylester (2)

To 1 (0.8g, 3.1mmol) dissolved in CH₃CN (10 mL) and DMF (5 mL), 2M phosphate buffer (pH=8, 10 mL) and *N*,*N*-bis[(*tert*-butoxycarbonyl) methyl] -2-bromoethyl-amine (3.78g, 10.7mmol) prepared previous report was added. The resulting mixture was vigorously stirred for 48 hrs at room temperature. Organic layer was extracted with CH₂Cl₂ and repeated three times. The solvent was evaporated to afford a residue as pale yellow oil form. Purification was performed using flash column chromatography with gradient condition (Hexane/Ethyl acetate, from 100:0 to 0:100 for 30 min) to gave a product as pale oil form with 76 % yield of **2**.

2.1.4 Hydrolysis (3)

Hydrolysis was performed with 3N-HCl at 100° for 20 mins. After evaporation, recrystalization was performed by using CH₃OH and diethyl ether.

2.2 Preparation of ^{99m}Tc-DTPA complex

After the preparation of 2 mg of SnCl₂ dissolved in 0.1N HCl (1 ml) under inert atmosphere, 0.1 ml of SnCl₂ solution was added to another vial containing 0.5 mg of 3 in N₂ purged HCl solution (1ml, pH=5) and then 0.2 ml of freshly eluted ^{99m}TcO₄⁻ (3 mCi) from ⁹⁹Mo-^{99m}Tc generator was added. The reaction mixture was gently stirred for 10 min at room temperature and filtered through 0.22 $\mu\ell$ membrane filter. ITLC test revealed labeling yield as 97 %.

Labeling efficiency (%) = $100 - {}^{99m}\text{TeO}_4 - {}^{99m}\text{TeO}_2$



Fig. 1 Radiochromatogram of lysine based DTPA complex; Conditions; developing solvent(a) MEK, (b) 0.9% saline; stationary phase (ITLC-SG)

3. Conclusion

We established the preparation method for lysine based DTPA as a bifunctional chelating agent (BFCA). This established method for the synthesis of DTPA derivative with sustaining chelating power is very useful for conjugation with other molecules for the development of medical imaging agents and therapeutic agents.

REFERENCES

[1] K. Kimpe, T.N. Parac-Vogt, S. Laurent, C. Pierart, L.V. Elst, R. N. Muller, and K. Binnemans, Potential MRI Contrast Agents Based on Micellar Incorporation of Amphiphilic Bis(alkylamide) Derivatives of [(Gd-DTPA)(H₂O)]²⁻, *Eur. J. Inorg. Chem.* p. 3021-3027, 2003.

[2] S. Liu, E. Cheung, M. Rajopadhye, N. E. Williams, K. L. Overoye, and D. S. Edwards, Isomerism and Solution Dynamics of ⁹⁰Y-Labeled DTPA-Biomolecule Conjugates, *Bioconjugate Chem.* vol. 12, p. 84-91, 2001.

[3] D. Rattat, C. Terwinghe, and A. Verbruggen, Comparison of 'classic' ^{99m}Tc(CO)₃-DTPA and ^{99m}Tc(CO)₂(NO)-DTPA, *Tetrahedrron*, vol. 61, p. 9563-9568, 2005.

[4] H. A. Tang, S. Yang, and R. D. Yang, A Mild and Efficient Method of Synthesis of a Series of New Multidentate Ligands, *Synthetic Commun*, vol. 30, No. 16, p. 2811-2815, 2003

[5] A. Scozzafava, L. Menabuoni, F. Mincione, and C. T. Supuran, Carbonic Anhydrase Inhibitors. A General Approach for the Preparation of Water-Soluble Sulfonamides Incorporating Polyamino-Polycarboxylate Tails and of Their Metal Complexes Possessing Long-Lasting, Topical Intraocular Pressure-Lowering Properties, *J. Med. Chem.* vol. 45, p. 1466-1476, 2002

[6] J. M. Couchet, J. Azema, P. Tisnes, and C. Picard, Sensitization of europium(III) luminescence in bis(bipyridine) DTPA and DTTA-based ligands: effect of the deletion of amide groups, *Inorg. Chem. Commun.* vol. 6, p. 978-981, 2003

[7] M. Ligeti, O. Gunduz, A. Magyar, E. Kato, A. Z. Ronai, C. Vita, I. Varga, F. Hudecz, G. Toth, A. Borsodi, and S. Benyhe, Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides, *PEPTIDES*, vol. 26, p. 1159-1166, 2005